Koers Beleave Inc. Canadian Securities Exchange
Aandelen
BE
CA0775611084
Farmaceutische producten
Omzet 2018 | - | Omzet 2019 | 2,37 3,25 2,22 | Marktkapitalisatie | 30,37 mln. 41,51 mln. 28,4 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2018 | -12 mln. -16,4 mln. -11,22 mln. | Nettowinst (verlies) 2019 | -33 mln. -45,11 mln. -30,86 mln. | EV/omzet 2018 | - |
Nettoliquiditeiten 2018 | 5,2 mln. 7,11 mln. 4,86 mln. | Nettoschuld 2019 | 10,32 mln. 14,1 mln. 9,65 mln. | EV/omzet 2019 | 17.137.012 x |
K/w-verhouding 2018 |
-4,72
x | K/w-verhouding 2019 |
-0,76
x | Werknemers | - |
Dividendrendement 2018 * |
-
| Dividendrendement 2019 |
-
| Vrij verhandelbaar | 98,39% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | - | 26-05-00 | |
Roger Ferreira
CTO | Chief Tech/Sci/R&D Officer | - | 15-12-15 |
Kevin Keagan
BRD | Director/Board Member | - | 24-10-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Roger Ferreira
CTO | Chief Tech/Sci/R&D Officer | - | 15-12-15 |
Founder | - | 26-05-00 | |
Kevin Keagan
BRD | Director/Board Member | - | 24-10-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+35,04% | 5,92 mld. | |
-15,13% | 4,51 mld. | |
-9,75% | 3,15 mld. | |
+2,14% | 3,1 mld. | |
-6,82% | 2,42 mld. | |
+47,87% | 1,97 mld. | |
-7,89% | 1,68 mld. | |
+0,09% | 1,65 mld. | |
-12,97% | 1,53 mld. |